Global Norethisterone Market Size, Share, and Trends Analysis Report, By Application (Estrogen, Contraceptive, Functional Uterine Hemorrhage, Dysmenorrhea, Endometrial Hyperplasia, and Other), Forecast (2022-2028)

The global norethisterone market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Norethisterone is used to treat heavy periods, painful periods, irregular periods, and periods that are more frequent than normal. It is also prescribed to manage premenstrual tension as well as to treat endometriosis and breast cancer. The global norethisterone market is growing due to the increasing prevalence of menstrual problems globally. According to an article published by the US National Library of Medicine in January 2018, a cross-sectional study was conducted in the health colleges of Immam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, where 91.0% of the students were suffering from some kind of menstrual problem. According to an article published by the US National Library of Medicine in March 2019, an estimation of 14.2% of adult women aged 19 to 54 years reported having irregular menstruation. It also states that the prevalence of irregular menstruation varies from 5.0% to 35.6% depending on age, occupation, and country of residence.

 

Additionally, the rising prevalence of endometrial hyperplasia among women globally is also boosting the demand for norethisterone. According to the US National Library of Medicine, an estimation of 213 per 100,000 women in the early 50s and 56 per 100,000 women in the early 60s are diagnosed with endometrial hyperplasia. Furthermore, endometrial hyperplasia leads to endometrial malignancy, which is considered to be the most common gynecologic cancer in the US. According to the American Cancer Society, it is also the fourth most common cancer in women in the US. It is estimated that 65,950 women will be diagnosed with gynecologic cancer and 12,550 women will succumb to this malignancy in 2022. Therefore, the increasing prevalence of endometrial malignancy is also boosting the growth of the global norethisterone market.

 

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance, in May 2020, AbbVie Inc. received USFDA approval for ORIAHNN with the composition elagolix, estradiol, and norethindrone acetate capsules as the first oral medication for the management of heavy menstrual bleeding due to uterine fibroids in premenopausal women and is available in the US market from June 2020. Similarly, in May 2021, Pfizer Inc. and Myovant Sciences GmbH received USFDA approval for MYFEMBREE with the composition relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, the first once-daily treatment for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

 

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Mylan N.V., Eli Lilly and Co., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., and Solvay,among others.

 

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

 

Global Norethisterone Market Report by Segment

By Application

• Estrogen
• Contraceptive
• Functional Uterine Hemorrhage
• Dysmenorrhea
• Endometrial Hyperplasia
• Other

 

Global Norethisterone Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa